Candel Therapeutics (CADL) Cash from Financing Activities (2020 - 2025)

Candel Therapeutics (CADL) has 6 years of Cash from Financing Activities data on file, last reported at $43.9 million in Q4 2025.

• For the quarter ending Q4 2025, Cash from Financing Activities fell 52.24% year-over-year to $43.9 million; the trailing twelve-month figure through Dec 2025 stood at $56.1 million (down 40.5% YoY), and the FY2025 full-year result was $56.1 million, down 40.5% from the prior year.
• Cash from Financing Activities climbed to $43.9 million in Q4 2025, from -$3.4 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $91.9 million in Q4 2024 to a low of -$3.4 million in Q3 2025.
• A 5-year average of $16.1 million and a median of $333000.0 in 2021 frame the typical range for Cash from Financing Activities.
• Across the five-year window, Cash from Financing Activities tumbled 436.11% in 2023 and jumped 76061.16% in 2024, its largest moves.
• Tracing CADL's Cash from Financing Activities over 5 years: stood at $71.4 million in 2021, then plunged by 99.95% to $36000.0 in 2022, then plunged by 436.11% to -$121000.0 in 2023, then jumped by 76061.16% to $91.9 million in 2024, then sank by 52.24% to $43.9 million in 2025.
• Business Quant data shows CADL's Cash from Financing Activities at $43.9 million in Q4 2025, -$3.4 million in Q3 2025, and $17.4 million in Q2 2025.